Latest Articles and Analysis

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.